Mayo Clinic: Ovarian Cancer Subtypes May Predict Response to Bevacizumab

CHICAGO — Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. Results of the research were presented today at the 2014 American Society of Clinical Oncology Annual Meeting. The addition of bevacizumab to standard therapy extended progression-free survival more for [...]
Source: News from Mayo Clinic - Category: Databases & Libraries Source Type: news